Devyser has been awarded a tender for Devyser RHD, its product for non-invasive fetal RHD status in maternal plasma during pregnancy. The tender with Wales Blood Services covers fetal RHD testing in Wales and is valid for a period of three years, with the potential of a two-year extension. Indicative order value is estimated to amount to 1 million SEK annually.
"This is a strategic breakthrough in the UK market, and I am very proud of the entire team who made this happen", says CEO Fredrik Alpsten. "National and regional screening programs represent important opportunities for us and securing this tender is another confirmation of our RHD product's competitiveness in international tenders."
Devyser RHD is a highly sensitive CE-IVD labelled QPCR test to conduct accurate non-invasive screening for fetal RHD that helps clinicians avoid untargeted and unnecessary treatment.
The information was submitted for publication, through the agency of the contact persons below, December 5, 2023 at 11:30 CET.
For more information, please contact:
Fredrik Alpsten, CEO
Email: fredrik.alpsten@devyser.com
Telephone: +46 70 667 31 06
Theis Kipling, CCO
Email: Theis.kipling@devyser.com
Telephone: +46 73 598 07 76
About Devyser
Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 50 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.
Devyser was founded in 2004 and is based in Stockholm, Sweden with eight in-house sales offices in Europe and the US. The company also runs Devyser Genomic Laboratories, a CLIA certified laboratory in Atlanta, US. In 2022, Devyser's quality management system was certified according to the IVDR and a number of the company's products have since been certified according to the IVDR.
Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB.